Biogen completes Nightstar acquisition
The companies announced the acquisition in March this year, with the value estimated at approximately $800 million.
Read More
Tag: Sycona
Gyroscope and Orbital to create retinal gene therapy company
The two units belong to Sycona, who will own 82% of the company.
Read More
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
